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must have at least 1 prior MDD diagnosis (ICD-9-CM: 296.2 or 296.3), but no 
prior diabetes (ICD-9-CM: 250.xx) or bipolar disorder (ICD-9-CM: 296.4x–296.8x) 
diagnosis. The non-duloxetine patients were matched to the duloxetine patients 
via propensity scoring (1:1 ratio), controlling for differences in demographics, comor-
bidities, prior opioid use, and pain levels in the 12 months pre-index period. Paired 
t-tests were used to compare health care utilization over the 12 months post- 
index period including outpatient visits, emergency department (ED) visits, hospital 
admissions and length of hospital stay. Chi-square tests were used to compare 
percentages of patients with hospitalization or ED visit. RESULTS: The study 
sample included 878 patients (duloxetine: n  439; non-duloxetine: n  439) with 
comparable baseline characteristics. Compared with duloxetine patients, non-dulox-
etine patients on average had 12.0 more outpatient visits (95% Conﬁdence Interval 
[CI]: 6.4–17.5, p  0.0001), 0.16 more hospital admissions (CI: 0.07–0.26, p  0.001), 
and 0.79 more hospital days (CI: 0.17–1.41, p  0.013). Additionally, a higher per-
centage of non-duloxetine patients was hospitalized (17.8% vs. 10.9%, p  0.004). 
No group difference was found in ED visits. CONCLUSIONS: Controlling for cross-
cohort differences, VA patients who were treated with duloxetine were found to 
be associated with lower health care utilization than those treated with other 
antidepressants.
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OBJECTIVES: GAD is a chronic disease with waxing and waning of symptoms; 
exerting substantial economic and humanistic impact. To date, economic evaluations 
have been limited to time horizons of 12 months. This study develops a dynamic 
decision model, quantifying the lifetime cost-of-illness (COI) for GAD (direct and 
indirect costs). METHODS: TreeAge® software was used to develop an incidence-
based Markov model with 9 health-states (6-month cycles): Family physician assess-
ment (initial), Specialist assessment for 2nd and 3rd line therapies, Maintenance 
therapies, Treatment discontinued and Death (absorbing). Patients seeking treatment 
enter the model between the ages of 18–80 and subject to age of onset. Pharmaco-
therapy based on Canadian Psychiatric Association (CPA) guidelines; revised and 
validated by an expert panel. Meta-analysis of CPA-cited evidence populated remis-
sion and response rates. Published literature determined absenteeism, treatment 
 discontinuation, onset of illness, and relapse rates. Physician, pharmacotherapy, hos-
pitalization costs based on published public (Province of Ontario) rates. All cause 
mortality (2000–2002) and hourly wage rates (2008) published by Statistics Canada. 
COI was reported in 2008 Canadian dollars, discounted at 5%. A total of 10,000 
iterations were used for 1st order micro-simulation. RESULTS: Mean lifetime COI/
patient  $6671(SD  $4678). Mean age of onset  48 years. Mean (SD) tracker values: 
Relapse/patient  1(1.02); Treatment resistant patients  20%(40%); Discontinued 
treatment time  13(8) years. Absorbing state (Death) captures 89% of patients. The 
range of uncertainty for relapse (1–5%) and cost of absenteeism ($0-$6,071) exerted 
the highest impact of all variables on mean COI $5,000–8,000 and $1,000–$12,000 
respectively. Breakdown cost analysis: 82% absenteeism, 8% pharmacotherapy, 7% 
physician, 2% hospitalization. 85% of all patients discontinued treatment by 4th year). 
CONCLUSIONS: This is the ﬁrst known study to model the course of GAD over a 
patient’s lifetime and quantify COI. Absenteeism contributes substantially to the COI 
for GAD. Relatively low attribution of pharmacotherapy cost to COI possibly due to 
treatment discontinuation.
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OBJECTIVES: To measure the total direct cost of depression and its distribution to 
different services using administrative databases from Alberta service providers. 
METHODS: We analyzed available administrative databases from Alberta Health and 
Wellness and the Alberta Mental Health Board from 2005–2006. The following cost 
information was obtained: psychiatric care, community mental health visits, regional 
inpatient and outpatient services, emergency room visits, and physician visits. Records 
were selected if the primary diagnosis for the service was depression disorder using 
2006 dollar values. Data was analyzed by age group. RESULTS: Depression in Alberta 
had a direct health care cost of $97 M in 2005–2006, representing 1.1% of the prov-
ince’s total health care costs. The treated prevalence of depression in 2005–2006 was 
estimated at 13%. The greatest cost driver was physician services ($42.6 M), followed 
by acute inpatient costs ($33.8 M). General practitioners incurred half of physician 
costs and treated nearly six times the number of individuals with depression than 
psychiatrists. Per capita cost to treat depression increases with age, with seniors rep-
resenting the highest cost per individual. Older adults tend to use and incur a greater 
cost in inpatient services, while outpatient or physician services are more heavily used 
by younger age groups. CONCLUSIONS: The estimated $97 M cost of depression in 
Alberta is likely to be an underestimation. We included individual data with a primary 
diagnosis of depression and could not include drug data or privately funded services. 
Our ﬁndings are consistent with previous research that people with depression are 
treated more frequently in primary care and that the cost to treat depression increases 
with age. Depression continues to be a heavy cost burden throughout Alberta and 
worldwide.
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OBJECTIVES: The main objective is to assess resource utilization and cost of schizo-
phrenia as well as cost drivers using a prospective cohort that followed a representative 
sample of 288 French patients. METHODS: This study is the ﬁrst comprehensive 
prospective study on cost of schizophrenia. Patients were randomly selected from three 
deﬁned catchment areas located in the North, Centre and South of France. Unit costs 
were based on the most valid available data, mainly health insurance and French 
public sources. Costs were deﬁned based on society perspective. Direct cost included 
treatment provided in inpatient services, intermediate facilities, outpatient visits and 
medication costs. Indirect costs were considered as productivity loss for unemployed 
or sick leave patients in working age. RESULTS: Average patient direct costs yield 
a3534, break down as 39.3% for inpatient treatment, 37.7% for day clinic, and 
16.1% for medication. The remaining includes visits to psychiatrists, GP’s, psycholo-
gists and other physicians. Assuming 1% prevalence of schizophrenia, the estimation 
of annual direct costs yields a1, 581, 111, 600, and indirect cost of schizophrenia 
linked to productivity loss in France yields a2, 214, 488, 006. Several cost drivers 
were identiﬁed: relapse during the follow-up period, positive symptoms of schizophre-
nia, and depressive symptoms at baseline predict higher costs, while satisfaction with 
their health or negative symptoms of schizophrenia at baseline was linked with lower 
costs. CONCLUSIONS: This study highlights the heavy societal burden of schizophre-
nia in France, of which hospitalization (day and full time) services account for 77%. 
Any attempt to anticipate and prevent hospitalization might have signiﬁcant effect on 
the cost of schizophrenia. Such intervention is likely to be cost effective.
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OBJECTIVES: Bipolar disorder (BD) is a long-term condition that has a high impact 
on patients, families, health care systems and society. One of the main challenges in 
mental health is to determine the burden associated with it. The purpose is to establish 
the different perspectives and measures used to asses the burden of BD. METHODS: 
A systematic review was performed to identify studies in PUBMED, MEDLINE, 
EMBASE and Cochrane library. The search strategy used the MeSH terms: “bipolar 
disorder” & “cost of illness”, combined with “burden of disease”, “disease burden” 
& “burden of illness”. There weren’t constrains on date or language. Titles and 
abstracts were examined by reviewers, selecting for inclusion articles reporting an 
explicit aim to evaluate the burden of BD, measured by prevalence, morbidities associ-
ated, lost of quality of life, disabilities, impairments and/or costs. Articles were classi-
ﬁed into 4 categories, depending on focus studied: 1) patients; 2) caregivers (family, 
partners); 3) health care-system; and 4) society. RESULTS: A total of 188 articles were 
identiﬁed, 32 met study criteria. Eleven studies were reviews, and 21 were manuscripts, 
classiﬁed as 53.1% caregivers (n  17), 28.2% health care-system (n  10), 15.6% 
patients (n  5) and 3.1% society (n  1). The main outcome measures were: distress 
and subjective burden in caregivers scope, costs in health care-system, morbidity in 
patients and a set of all (prevalence, patient-related issued, disabilities and costs) in 
society. CONCLUSIONS: Concept of burden of disease varies depending on the 
studies perspectives and researchers concern. Our study suggests that the main interest 
when evaluating the burden of BD is focused on assessing the impact of the disease 
on relatives. As BD causes a high level of impairments and disabilities, that affects 
specially to caregivers, costs associated with it are difﬁcult to estimate. Additional 
research is needed in order to determine them properly.
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OBJECTIVES: Data concerning costs of illness in patients with schizophrenia are          
scarce in Germany. Aim of this claims data analysis was to examine the costs of 
schizophrenia from the perspective of a major statutory health insurance fund. 
METHODS: A nation-wide database was used to evaluate the costs of schizophrenia           
in 2006. All patients with schizophrenia (ICD F20) were identiﬁed via a special algo-
rithm based on claims data. All schizophrenia related costs for outpatient care, inpa-
tient care, medications, rehabilitation, occupational therapy, and sick leave payments 
were analysed. RESULTS: Data from 11,513 patients were available, with 47%        
being female (and 46 years of age). Mean costs of EUR 4,966 in the year 2006 were 
incurred from the health insurance perspective. A total of a2924 (59 %) were incurred 
by inpatient care, and a1333 (27 %) were due to medication. A total of a421 (8 %) 
resulted from schizophrenia related outpatient psychological specialists visits. Costs 
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for rehabilitation were a27 (a1 %), for occupational therapy a14 (a1 %). Costs for 
sick leave payments came to a247 (5%) in 2006. Costs increase when a patient had 
an inpatient episode. A patient with at least one inpatient visit causes average annual 
costs of a15,487 (inpatient: a12,938; medication: a1552; outpatient: a322; rehabilita-
tion: a108; occupational therapy: a16; sick leave payments: a551). A total of 2602 
(23 %) patients had at least one inpatient visit in 2006. CONCLUSIONS: The 
major cost driver in schizophrenia from a health insurance perspective in Germany is 
inpatient care as well as to a lesser extent medication costs. Patients with at least 
one inpatient episode cause threefold cost compared with the average cost of 
schizophrenia.
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OBJECTIVES: To identify direct and indirect costs associated with adult ADHD. 
METHODS: An analysis of health care claims databases (MarketScan) identiﬁed 
adults (aged q 18) diagnosed with ADHD q 2 times within a 12-month period between 
2002 and 2007, and with q1 diagnosis of ADHD or an ADHD-related prescription 
claim in 2006. Control patients with no diagnosis of ADHD were randomly matched 
3:1 to ADHD patients based on gender, age, region, and presence of capitated services. 
Direct health care costs were based on inpatient visits, ER visits, outpatient services 
and visits, and prescriptions. Indirect costs included work absences (WA), short- 
term disability (STD), and worker’s compensation (WC). Comorbidity was assessed 
through the Deyo-Charlson Comorbidity Index (CCI) and the presence of speciﬁc 
nonpsychiatric and psychiatric comorbidities known to be associated with ADHD 
from the medical literature. RESULTS: A total of 31,752 ADHD patients and 95,256 
controls were identiﬁed. Compared with controls, ADHD patients had higher mean 
costs associated with health care ($4306 vs. $2418, P  0.0001) and STD ($743 vs. 
$424, P  0.0001). There were no signiﬁcant differences in mean costs associated with 
WA ($3304 vs. $3404, P  0.5686) or WC ($356 vs. $380, P  0.8689). Although 
the absolute difference was small, the mean CCI was signiﬁcantly lower for ADHD 
patients than for controls (0.15 vs. 0.18, P  0.0001). Compared with controls, ADHD 
patients were more frequently diagnosed with most of the comorbidities investigated. 
The top 3 diagnoses with the largest differences in cohort comorbidity rates were 
injuries, depression, and bipolar disorder (P  0.0001). CONCLUSIONS: Patients 
with ADHD had medical expenditures almost twice as high as patients without ADHD 
and were more likely to seek medical care for injuries. Given a 4.4% prevalence rate 
of adult ADHD in the United States, the overall societal and direct medical costs for 
adult ADHD may be signiﬁcant. Supported by funding from Shire Development Inc.
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OBJECTIVES: To analyze treatment patterns and costs following ﬁrst-line treatment 
of major depressive disorder (MDD). METHODS: Using a retrospective cohort design 
and claims data (January 2003-March 2008), we examined patients who began ﬁrst-
line monotherapy for MDD, and followed them for 1 year through successive lines of 
therapy. Patients had: at least 1 health care claim due to MDD between January 2004 
and March 2007; initiated MDD monotherapy within 7 days of ﬁrst MDD diagnosis 
(index date); no previous exposure to index monotherapy in the 180 days prior to 
index date; continuous enrollment 6 months prior to and 12 months post index date. 
The adjusted average weekly health care cost attributable to mental health problems 
was compared across lines of treatment using 2-part regression models with log 
transformation of costs. RESULTS: A total of 14,601 patients were identiﬁed. Selec-
tive serotonin reuptake inhibitors were the leading treatment choice across ﬁrst, 
second, and third lines of therapy, followed by benzodiazepines, buproprion, and 
serotonin-noradrenaline reuptake inhibitors. Patients either continued with their index 
treatment (6.7%), added a new therapy (27.2%), switched to another therapy 
(59.1%), or discontinued treatment (7.1%). Of the 12,597 patients who added or 
switched therapy, 5714 received third-line therapy, and of these, 2227 progressed to 
fourth-line therapy within the ﬁrst year. Average weekly costs for patients initiating 
1, 2 and 3 lines of therapy were $70, $68, and $95, respectively. Patients still not 
achieving an adequate response during fourth-line therapy incurred between $143 and 
$334 per week in health care costs. Patients who switched or added another therapy 
generally incurred the highest costs. CONCLUSIONS: Patients with MDD who do 
not respond to successive lines of treatment incur higher mental health costs than 
responsive patients. This pattern is particularly evident between second and third, and 
between third and fourth lines of treatment. Supported by funding from AstraZeneca 
Pharmaceuticals LP.
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OBJECTIVES: To carry-out a 6-month cost-effectiveness analysis (CEA) of the effect 
of Pregabalin (PGB) versus Usual Care (UC) in Duloxetine-refractory out-patients with 
Generalized Anxiety Disorder (GAD) treated according with usual medical practice in 
Mental Health Centers in Spain. METHODS: This CEA used secondary data extracted 
from a 6-month cohort prospective observational study (the ADAN study) designed 
to ascertain cost and health care resources utilization in subjects with GAD (DSM-IV 
criteria). Duloxetine-refractory subjects were deﬁned as those who claimed of persis-
tent symptoms of anxiety and showed suboptimal response (HAM-Anxiety scale q 16) 
after a course of standard doses of duloxetine for 6 month. At baseline, patients could 
switch to PGB, monotherapy or add-on, or to UC which could include ISRS/ISRN/
other antidepressants, benzodiazepine, anti-epileptics different than PGB or a combi-
nation. Health outcomes included quality-adjusted life years (QALYs) gain by EQ-5D 
questionnaire. The perspective of CEA was that of a 3rd-payer in year 2009. Sensitivity 
analysis was performed by means of bootstrapping techniques (10000 re-samples were 
obtained) in order to obtain a cost-effectiveness acceptability curve. RESULTS: A total 
of 132 duloxetin-refractory subjects (mean baseline HAM-A; 25.6 pts) were identiﬁed; 
103 and 29 in the PGB and UC groups, respectively. Compared with UC, PGB therapy 
was associated with signiﬁcant QALY gain after 6 months of treatment; 0.1191 o 
0.1163 vs 0.0810 o 0.0777, p  0.043, but higher health care costs; a1,402.1 o 849.1 
vs a1,051.5 o 789.1, p  0.048. The deterministic ICER ratio was a9,210 per QALY 
gained with a re-sampling ICER of a11,234 (95 CI: 1,591–20,877). The 90% of re-
samples fold below a20,513 threshold and 95% below a29,901. CONCLUSIONS: 
Despite the small sample and observational design, this evaluation could suggest that 
pregabalin may be cost-effective in comparison with usual care in duloxetine-refrac-
tory subjects with Generalized Anxiety Disorders managed in Mental Health Centers 
under usual medical practice in Spain.
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OBJECTIVES: To carry-out a 6-month cost-effectiveness analysis (CEA) of the effect 
of Pregabalin (PGB) versus ISRS/ISRN in benzodiazepine refractory out-patients with 
Generalized Anxiety Disorder (GAD) treated according with usual medical practice in 
Mental Health Centers in Spain. METHODS: This CEA used secondary data extracted 
from a 6-month cohort prospective observational study (the ADAN study) designed 
to ascertain cost and health care resources utilization in subjects with GAD (DSM-IV 
criteria). Benzodiazepine-refractory subjects were deﬁned as those who claimed of 
persistent symptoms of anxiety and showed suboptimal response (HAM-Anxiety scale 
 16) after a course of standard doses of benzodiazepines, alone or in combination, 
for 6 months. At baseline, patients could switch to PGB monotherapy or add-on or 
to ISRS/ISRN along or in combination. Outcomes included quality-adjusted life years 
(QALYs) gain using the EQ-5D questionnaire. As the perspective of CEA was that of 
a 3rd-payer, only health care resources use and corresponding costs were computed 
in year 2009. Sensitivity analysis was performed by means of bootstrapping techniques 
(10000 re-samples were obtained) in order to obtain a cost-effectiveness acceptability 
curve. RESULTS: A total of 231 benzodiazepine-refractory subjects (mean baseline 
HAM-A; 25.1 pts) were identiﬁed; 116 in the PGB and 115 in the ISRS/ISRN group, 
respectively. Compared with ISRS/ISRN, PGB therapy was associated with higher 
QALY gain; 0.1126 o 0.09857 vs. 0.1008 o 0.09460, but increased health care costs; 
a998.1 o 691.5 vs. a894.2 o 648.5. The deterministic ICER ratio was a8,89 per QALY 
gained with a re-sampling ICER of a6,214 (95 CI: 1,825–10,604). The 90% of re-
samples fold below a26,556 threshold and 92% below a30,000. CONCLUSIONS: 
Despite the observational design of the primary study, this evaluation could suggest 
that pregabalin may be cost-effective in comparison with ISRS/ISRN in benzodiazepine 
refractory out-patients with Generalized Anxiety Disorders managed in Mental Health 
Centers under usual medical practice in Spain.
